# Hour 09: 09:00-09:59 - Peak Morning Operations

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 09 represents the peak arrival hour of the 24-hour on-demand simulation
cycle with 15 new patient arrivals, the highest volume in any single hour.
All 3 surgical suites are occupied simultaneously at 09:00, robot utilization
reaches approximately 72% (the highest recorded so far), and maximum concurrent
patient count on-site reaches approximately 28. One Grade 1 adverse event
occurs (post-surgical hypotension in PAT-ODMND-0024) and is managed within
10 minutes. Site PSL rises to 64.5 (Advanced Site).

## Site Status at 09:00

- Total patients on-site: approximately 28 (peak concurrent)
- Active procedures: multiple concurrent across all wings
- Robots in active mode: approximately 21 of 29 instances
- Robots in standby mode: approximately 8
- Robots in maintenance: 0
- Queue length: 2-3 patients waiting at any time
- Site safety officer on duty: SSO-D1 (day shift)
- Surgical suites: ALL 3 occupied (P0024 finishing, P0032 ongoing, P0044 starting)
- Robot utilization: approximately 72% (PEAK so far in simulation)

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage/Grade | ECOG | Robot Assigned |
|-----------|------|-----|-----|-------------|-------------|------|---------------|
| PAT-ODMND-0044 | 09:00 | 60 | M | Mediastinal tumor | Stage II | 1 | SURG-03 |
| PAT-ODMND-0045 | 09:04 | 35 | F | Forearm sarcoma | Grade II | 0 | COBOT-03 |
| PAT-ODMND-0046 | 09:07 | 68 | F | Meningioma | Stage I | 0 | RTPOS-02 |
| PAT-ODMND-0047 | 09:10 | 7 | F | Pediatric AML | - | 1 | COMPN-05 |
| PAT-ODMND-0048 | 09:14 | 55 | M | NSCLC adenocarcinoma | Stage IIIA | 1 | TRACK-01 |
| PAT-ODMND-0049 | 09:18 | 43 | F | Parotid tumor | Stage II | 0 | NEEDLE-02 |
| PAT-ODMND-0050 | 09:22 | 61 | M | HCC | Stage II | 1 | IMAGE-01 |
| PAT-ODMND-0051 | 09:25 | 15 | M | Pediatric osteosarcoma | - | 1 | HUMAN-01, REHAB-01 |
| PAT-ODMND-0052 | 09:28 | 74 | F | Liver mets (colorectal) | Stage IV | 2 | STEER-02 |
| PAT-ODMND-0053 | 09:32 | 50 | M | NSCLC squamous | Stage IIIA | 1 | TRACK-02 |
| PAT-ODMND-0054 | 09:36 | 46 | F | Brain metastases | Stage IV | 1 | RTPOS-03 |
| PAT-ODMND-0055 | 09:40 | 28 | M | Forearm sarcoma | Grade I | 0 | COBOT-04 |
| PAT-ODMND-0056 | 09:44 | 64 | F | HCC | Stage III | 1 | IMAGE-02 |
| PAT-ODMND-0057 | 09:48 | 69 | M | Femur osteosarcoma | - | 2 | REHAB-02 |
| PAT-ODMND-0058 | 09:52 | 12 | F | Pediatric ALL | - | 1 | COMPN-01 |

PAT-ODMND-0044 is a 60-year-old male with Stage II mediastinal tumor presenting
for scheduled robotic thoracoscopic resection. He selected the 09:00 window
through the patient portal. ECOG 1. Assigned to Surgical Suite 3 (SURG-03).
This arrival fills all 3 surgical suites simultaneously for the first time
in the simulation.

PAT-ODMND-0045 is a 35-year-old female with Grade II forearm soft-tissue
sarcoma presenting for cobot-guided needle biopsy. ECOG 0. Assigned to
COBOT-03 at Biopsy Station 3.

PAT-ODMND-0046 is a 68-year-old female with Stage I meningioma presenting
for RT positioning and mask fitting in preparation for stereotactic
radiosurgery. ECOG 0. Assigned to RTPOS-02 in Vault 2.

PAT-ODMND-0047 is a 7-year-old female with pediatric acute myeloid leukemia
(AML) presenting for companion robot anxiety management session prior to
chemotherapy. ECOG 1. Assigned to COMPN-05. Parent/guardian present per
21 CFR Part 50 Subpart D pediatric protections.

PAT-ODMND-0048 is a 55-year-old male with Stage IIIA NSCLC adenocarcinoma
presenting for RT motion-tracking treatment. Fraction 8 of 30, 2 Gy per
fraction. ECOG 1. Assigned to TRACK-01 in Vault 1.

PAT-ODMND-0049 is a 43-year-old female with Stage II parotid tumor presenting
for CT-guided needle placement for biopsy. ECOG 0. Assigned to NEEDLE-02.

PAT-ODMND-0050 is a 61-year-old male with Stage II hepatocellular carcinoma
presenting for robotic ultrasound liver assessment. ECOG 1. Assigned to
IMAGE-01.

PAT-ODMND-0051 is a 15-year-old male with pediatric osteosarcoma presenting
for humanoid-guided physical therapy preparation followed by rehabilitation
exoskeleton session. ECOG 1. Dual robot assignment: HUMAN-01 then REHAB-01.
Parent/guardian present per 21 CFR Part 50 Subpart D.

PAT-ODMND-0052 is a 74-year-old female with Stage IV colorectal liver
metastases presenting for steerable needle ablation. ECOG 2. Assigned to
STEER-02. Higher ECOG status requires enhanced monitoring per ICH E6(R3)
Section 2.10.

PAT-ODMND-0053 is a 50-year-old male with Stage IIIA NSCLC squamous cell
carcinoma presenting for RT motion-tracking treatment. Fraction 5 of 30,
2 Gy per fraction. ECOG 1. Assigned to TRACK-02 in Vault 3. This creates
concurrent dual-vault RT tracking operations.

PAT-ODMND-0054 is a 46-year-old female with Stage IV brain metastases
presenting for RT stereotactic positioning and treatment planning. ECOG 1.
Assigned to RTPOS-03 in Vault 3 (after TRACK-02 session completes or in
sequential vault sharing).

PAT-ODMND-0055 is a 28-year-old male with Grade I forearm sarcoma presenting
for cobot-guided biopsy. ECOG 0. Assigned to COBOT-04.

PAT-ODMND-0056 is a 64-year-old female with Stage III HCC presenting for
robotic imaging assessment. ECOG 1. Assigned to IMAGE-02.

PAT-ODMND-0057 is a 69-year-old male with femur osteosarcoma presenting for
post-surgical rehabilitation exoskeleton session. ECOG 2. Assigned to REHAB-02.

PAT-ODMND-0058 is a 12-year-old female with pediatric ALL presenting for
companion robot session prior to scheduled treatment. ECOG 1. Assigned to
COMPN-01. Parent/guardian present per 21 CFR Part 50 Subpart D.

## Continuing Patients from Prior Hours

### PAT-ODMND-0024 - Surgery Completion
- Cancer: Mediastinal tumor
- Robot: SURG-01 (Surgical Suite 1)
- Surgery started: prior hour (approximately 06:40)
- Completion: 09:10 (successful, total duration approximately 150 minutes)
- Outcome: R0 resection (negative margins confirmed by intraoperative pathology)
- Estimated blood loss: 180 mL (within acceptable range)
- Post-surgical status: Transferred to Recovery Bay 1

### PAT-ODMND-0032 - Surgery Ongoing
- Cancer: Solid tumor (ongoing resection)
- Robot: SURG-02 (Surgical Suite 2)
- Surgery started: 08:15
- Expected completion: approximately 10:00 (next hour)
- Status at 09:59: Ongoing, stable vitals, no complications

## Active Procedures This Hour

### Surgical Procedure - PAT-ODMND-0024 Completion (06:40-09:10)
- Patient: PAT-ODMND-0024
- Robot: SURG-01 (Surgical Suite 1)
- Procedure: Robotic thoracoscopic mediastinal tumor resection (completing)
- 09:00 - Closure phase in progress
- 09:05 - Final hemostasis confirmed. Chest drain placed.
- 09:08 - Instruments withdrawn. Port sites closed.
- 09:10 - Procedure complete. R0 resection. Blood loss 180 mL.
- 09:12 - Patient extubated, transferred to Recovery Bay 1.
- Outcome: Successful. Specimen sent to pathology.

### Surgical Procedure - PAT-ODMND-0032 Ongoing (08:15-~10:00)
- Patient: PAT-ODMND-0032
- Robot: SURG-02 (Surgical Suite 2)
- Status: Main resection phase ongoing throughout hour 09
- Vitals: Stable. HR 68-74, BP 118-126/72-78, SpO2 99%.
- Blood loss this hour: approximately 60 mL (cumulative approximately 140 mL)

### Surgical Procedure - PAT-ODMND-0044 Start (09:15-ongoing)
- Patient: PAT-ODMND-0044
- Robot: SURG-03 (Surgical Suite 3)
- Procedure: Robotic thoracoscopic mediastinal tumor resection
- 09:00 - Arrival, check-in
- 09:05 - Pre-procedure safety matrix completed per 21 CFR 50.30
- 09:10 - Anesthesia induction
- 09:15 - First port inserted. Surgery commences.
- 09:20 - Tumor identification. Dissection begins.
- 09:30 - Mediastinal dissection in progress. Margins clear.
- 09:45 - Tumor mobilization. Vascular pedicle identified.
- 09:59 - Procedure ongoing, expected completion next hour.

### Cobot Biopsy - PAT-ODMND-0045 (09:12-09:30)
- Patient: PAT-ODMND-0045
- Robot: COBOT-03 (Biopsy Station 3)
- Procedure: Cobot-guided forearm soft-tissue needle biopsy
- Duration: 18 minutes
- Force applied: 2.8 N insertion force
- Needle trajectory accuracy: 0.3 mm deviation
- Sample cores obtained: 4
- Sample quality: Grade A
- Outcome: Successful. No post-procedure bleeding.

### RT Positioning - PAT-ODMND-0046 (09:16-09:42)
- Patient: PAT-ODMND-0046
- Robot: RTPOS-02 (Vault 2)
- Procedure: Meningioma stereotactic mask fitting and CT simulation
- Duration: 26 minutes
- Mask fit accuracy: 0.4 mm
- CT simulation: 124 slices, 1 mm thickness
- Digital twin: Meningioma model created, tumor volume 8.2 cm3
- Outcome: Successful. Treatment plan to be generated.

### Companion Session - PAT-ODMND-0047 (09:18-09:48)
- Patient: PAT-ODMND-0047 (7F, pediatric AML)
- Robot: COMPN-05 (Play Area 5)
- Session type: Pre-chemotherapy anxiety management
- Duration: 30 minutes
- Anxiety score: Pre-session 7/10, post-session 3/10
- Activities: Interactive storytelling, breathing exercises, procedure preview
- Parent present: Yes (per 21 CFR Part 50 Subpart D)
- Outcome: Anxiety reduced. Patient ready for chemotherapy preparation.

### RT Motion-Tracking - PAT-ODMND-0048 (09:22-09:42)
- Patient: PAT-ODMND-0048
- Robot: TRACK-01 (Vault 1)
- Procedure: Fraction 8 of 30, 2 Gy to left upper lobe NSCLC
- Duration: 20 minutes (calibration 3 min, treatment 15 min, exit 2 min)
- Beam gating efficiency: 93.8%
- Breathing amplitude: 3.8 mm
- Marker displacement: 1.6 mm average
- Dose delivered: 2.000 Gy (cumulative 16.0 Gy of 60.0 Gy)
- Outcome: Successful completion.

### Needle Placement - PAT-ODMND-0049 (09:28-09:58)
- Patient: PAT-ODMND-0049
- Robot: NEEDLE-02 (CT Suite 2)
- Procedure: CT-guided needle placement for parotid tumor biopsy
- Duration: 30 minutes
- CT guidance: 3 verification scans
- Needle placement accuracy: 0.5 mm from planned trajectory
- Proximity to facial nerve: 4.2 mm (safe margin maintained)
- Sample obtained: Yes, adequate tissue
- Outcome: Successful. No facial nerve compromise.

### Imaging Assessment - PAT-ODMND-0050 (09:30-09:48)
- Patient: PAT-ODMND-0050
- Robot: IMAGE-01 (Imaging Bay 1)
- Procedure: Robotic ultrasound liver assessment
- Duration: 18 minutes
- Probe pressure: 1.9 N average
- Image quality score: 8.4/10
- Tumor measurement: 32 x 26 mm (primary HCC lesion)
- Scan coverage: 94%
- Outcome: Successful. Digital twin liver model updated.

### Humanoid Therapy Prep - PAT-ODMND-0051 (09:33-09:48)
- Patient: PAT-ODMND-0051 (15M, pediatric osteosarcoma)
- Robot: HUMAN-01 (Therapy Station 1)
- Session: Physical therapy preparation and range-of-motion assessment
- Duration: 15 minutes
- ROM assessment: Knee flexion 82 degrees (post-surgical baseline)
- Gait analysis: Antalgic gait pattern, weight-bearing 60%
- Outcome: Baseline established. Patient transitioned to REHAB-01.

### Rehab Exoskeleton - PAT-ODMND-0051 (09:50-ongoing)
- Patient: PAT-ODMND-0051
- Robot: REHAB-01 (Rehabilitation Bay 1)
- Session: Assisted walking with lower-limb exoskeleton
- Started: 09:50, continuing into next hour
- Initial support: 70% body weight support
- Steps completed by 09:59: 42

### Steerable Needle Ablation - PAT-ODMND-0052 (09:38-ongoing)
- Patient: PAT-ODMND-0052 (74F, Stage IV colorectal liver mets)
- Robot: STEER-02 (Ablation Suite 2)
- Procedure: CT-guided steerable needle microwave ablation
- Started: 09:38
- Target: 2.4 cm metastatic lesion in right hepatic lobe
- Needle insertion accuracy: 0.4 mm from planned path
- Status at 09:59: Ablation in progress, target temperature 65 C
- Enhanced monitoring active due to ECOG 2 status

### RT Motion-Tracking - PAT-ODMND-0053 (09:40-09:58)
- Patient: PAT-ODMND-0053
- Robot: TRACK-02 (Vault 3)
- Procedure: Fraction 5 of 30, 2 Gy to right hilum NSCLC squamous
- Duration: 18 minutes
- Beam gating efficiency: 94.5%
- Breathing amplitude: 4.2 mm
- Marker displacement: 1.9 mm average
- Dose delivered: 2.000 Gy (cumulative 10.0 Gy of 60.0 Gy)
- Outcome: Successful. Concurrent dual-vault RT tracking confirmed.

### RT Positioning - PAT-ODMND-0054 (09:44-ongoing)
- Patient: PAT-ODMND-0054 (46F, brain metastases)
- Robot: RTPOS-03 (Vault 3, after TRACK-02 exits)
- Procedure: Stereotactic frame fitting and CT simulation for brain mets
- Started: 09:44
- Frame placement accuracy: 0.3 mm
- Status at 09:59: CT simulation in progress

### Cobot Biopsy - PAT-ODMND-0055 (09:48-ongoing)
- Patient: PAT-ODMND-0055
- Robot: COBOT-04 (Biopsy Station 4)
- Procedure: Cobot-guided forearm sarcoma biopsy
- Started: 09:48
- Status at 09:59: Biopsy in progress, 2 of 4 cores obtained

### Imaging Assessment - PAT-ODMND-0056 (09:52-ongoing)
- Patient: PAT-ODMND-0056
- Robot: IMAGE-02 (Imaging Bay 2)
- Procedure: Robotic ultrasound liver assessment for Stage III HCC
- Started: 09:52
- Status at 09:59: Scanning in progress

### Rehab Exoskeleton - PAT-ODMND-0057 (09:56-ongoing)
- Patient: PAT-ODMND-0057
- Robot: REHAB-02 (Rehabilitation Bay 2)
- Session: Post-surgical femur osteosarcoma rehabilitation
- Started: 09:56
- Status at 09:59: Initial calibration and fitting

### Companion Session - PAT-ODMND-0058 (09:55-ongoing)
- Patient: PAT-ODMND-0058 (12F, pediatric ALL)
- Robot: COMPN-01 (Play Area 1)
- Session: Pre-treatment anxiety management
- Started: 09:55
- Status at 09:59: Session in progress, interactive activities
- Parent present: Yes (per 21 CFR Part 50 Subpart D)

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0024 | 09:45 | To recovery | Post-surgical, Recovery Bay 1 (not discharged) |
| PAT-ODMND-0045 | 09:55 | Discharged | Post-biopsy observation complete, no complications |
| PAT-ODMND-0048 | 09:50 | Discharged | RT session complete, routine follow-up |

## Adverse Events

### AE-009-001: Post-Surgical Hypotension (Grade 1)
- Patient: PAT-ODMND-0024
- Time detected: 09:18
- Event: Mild hypotension, BP 92/58 mmHg (baseline pre-surgical 134/82)
- CTCAE Grade: 1 (mild, asymptomatic or mild symptoms)
- Context: Post-surgical transfer to Recovery Bay 1 following 150-minute
  mediastinal tumor resection with 180 mL blood loss
- Detection method: Automated vital sign monitoring (continuous) triggered
  hypotension alert when systolic fell below 95 mmHg threshold
- Response:
  - 09:18 - AI alert generated. SSO-D1 notified.
  - 09:19 - IV fluid bolus initiated (500 mL normal saline)
  - 09:20 - On-call emergency physician consulted remotely
  - 09:22 - BP trending upward: 98/62
  - 09:25 - BP recovered: 108/68
  - 09:28 - BP stabilized: 118/72 (within normal range)
- Outcome: Resolved within 10 minutes with IV fluid bolus
- Causality: Related to surgical blood loss (180 mL) and post-anesthesia
  vasodilation
- Follow-up: Increased monitoring frequency to every 5 minutes for 2 hours
- Reporting: Documented per ICH E6(R3) Section 2.10 adverse event detection.
  Classified as expected, non-serious per 21 CFR 312.32. No IND safety
  report required.

## Investigational Drug Administrations

None this hour. PAT-ODMND-0047 (pediatric AML) companion session is
pre-chemotherapy preparation; chemotherapy administration scheduled for
next hour pending companion session outcome and physician review.

## Site Utilization

- Overall robot utilization: approximately 72% (PEAK so far)
- Simultaneous surgical suites active: 3 of 3 (09:00-09:10, historic peak)
- Queue lengths: 2-3 patients waiting at peak times
- Average wait time: 8 minutes
- Robot cleaning cycles: 5 (COBOT-03, TRACK-01, IMAGE-01, COMPN-05, RTPOS-02)
- Maximum concurrent patients on-site: approximately 28

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: Peak operations maintained full GCP compliance despite
  highest patient volume. All 15 arrivals processed through standardized
  intake, consent verification, and pre-procedure safety protocols.
- Section 2.9.1: Complete audit trails maintained for all concurrent
  procedures. Surgical suite triple-occupancy logged with cross-reference
  to shared anesthesia gas supply monitoring.
- Section 2.10: Adverse event (AE-009-001) detected within 1 minute by
  automated monitoring. Response time well within the 5-minute escalation
  requirement. Documentation complete including causality assessment.
- Section 4.2.1: Data capture maintained at specification rates across all
  concurrent sessions despite peak load. Server room CPU utilization: 78%.
- Section 4.3.3: Network segmentation maintained under peak load. Robot
  control VLAN latency remained below 1 ms threshold.

### 21 CFR Part 50 - Adaption
- Section 50.25: All 15 new patients verified for previously completed
  informed consent including Physical AI system disclosure, USL readiness
  scores, and right to non-Physical AI alternatives.
- Section 50.30: Pre-procedure safety matrix completed for all procedures:
  authorization verified, patient identity confirmed, clinical data accessed
  via FHIR, robot readiness confirmed, environmental checks passed.
- Subpart D: Three pediatric patients (P0047, P0051, P0058) managed with
  enhanced protections. Parent/guardian present for all three. Age-appropriate
  consent/assent documented.

### 21 CFR Part 312 - Adaption
- Section 312.32: AE-009-001 classified as Grade 1, expected, non-serious.
  Causality assessment: related to procedure. No expedited IND safety
  report required. Event documented in trial safety database.
- Section 312.62: Investigator recordkeeping maintained for all patients
  including Physical AI system interaction logs, vital signs, and procedure
  records across all concurrent operations.
- Section 312.42: No clinical hold triggers identified despite peak volume
  and adverse event. Single Grade 1 AE within expected safety profile.

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. The concurrent dual-vault RT tracking operation
(TRACK-01 and TRACK-02 active simultaneously) demonstrates cross-instance
coordination capabilities consistent with the USL sharing dimension. The
triple-occupancy surgical suite operation reflects USL AI integration
scoring for the da Vinci dVRK platform (USL 7.1).
See physical-ai-oncology-trials/unification/usl/paper/usl_oncology_trials.tex.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. Hour 09 peak operations extend
this to 28 concurrent patients across 15 cancer types, validating the
scalability of on-demand orchestration from single-patient to population-
level throughput.
See physical-ai-oncology-trials/patient-journey/paper/patient_journey_paper.tex.
